Longeveron shares surge 12.16% intraday after U.S. patent grant for female sexual dysfunction stem cell therapy.

Longeveron Inc. surged 12.16% intraday following the U.S. Patent and Trademark Office’s grant of a patent for its mesenchymal stem cell therapy to treat female sexual dysfunction. The patent, covering methods to improve sexual quality of life in women, adds to the company’s aging-related disease portfolio and underscores its focus on unmet medical needs. Longeveron noted plans to pursue licensing or partnerships for commercialization, signaling potential revenue expansion. The news, coupled with recent Canadian patent approvals and positive Phase 2 Alzheimer’s trial data, reinforced investor confidence in its regenerative medicine pipeline. The stock’s sharp intraday rise aligns with the perceived value of intellectual property advancements and therapeutic differentiation in aging-related conditions.